The seed round was provided by Hampshire investment firm Ridown Group to support the rollout of Echo AI.
"Echo AI exists to help teams become more efficient, ensuring they stay on track and don’t miss outcomes, action points, and context in meetings. Productivity can suffer when people lose track of meetings, fail to remember what was said and agreed, and are not clear about the actions they are responsible for. Echo AI takes all the guesswork out of it, giving everyone an accurate record of the meeting and what was agreed. Businesses which have used Echo AI tell us that it creates time, reduces misunderstandings and slip-ups, and helps keep teams focused on tasks."
The Series D round was led by NEA and values the business at $2.1bn.
"This new investment will help us develop a new generation of AI-powered video experiences that are interactive, real-time, and personalized, offering possibilities we could have only imagined when we founded the company in 2017. I’m excited to bring these experiences to our over 60,000 customers, which range from the world’s largest brands to thousands of small businesses that use Synthesia to communicate internally and externally with unmatched engagement and efficiency,"
The round was led by We Venture Capital and Cross-Border Impact Ventures to fund the global commercialisation of its liquid biopsy technology.
"Having developed blood-based proteomic tests for lung cancer for over two decades, I appreciate the difficulty of detecting cancers early through liquid biopsy. Convinced that OXcan’s unique approach can address this clinical need, I feel privileged to join the team. Together, our plan is to offer this novel technological approach to large markets worldwide to start a new era of early detection and improve patient outcomes."
— Heinrich Roder, Senior Vice President of Research and Development
